BOONE, N.C. – Early clinical studies have shown that a fully digital, soft mist inhaler developed by Pneuma Respiratory can effectively deliver a number of different types of medicines to the lungs. “More than 40 million people suffer from asthma or COPD in the U.S.,” said James Bauler, director of business development at Pneuma Respiratory. “It’s well documented that patients have problems adopting the correct inhaler technique and thus receiving the expected dose of medication both with dry powder and existing metered-dose inhalers. With a proven team of technology and health care leaders, Pneuma expects to make significant gains in pulmonary drug delivery.” The device uses electronic breath actuation and a soft mist ejector. As a patient inhales, the ejector senses the breath and activates automatically. This allows the medication droplets to ride into the lungs on the patients’ breath, without propellants. Paired with a mobile app, the device is capable of delivering real-time dose verification data. Two clinical studies with COPD patients using small-molecule asthma and COPD medications validated the platform using bronchodilation as the outcome. A feature of the device is its ability to deliver different sized droplets of medicine via its droplet ejector technology, which allows the device to potentially target different areas of the lungs, said Bauler.
You are here: / / Pneuma develops digital inhaler